Bottom line
Is RYVTX a good fund? The bottom line
RYVTX is a share class of Inverse NASDAQ-100(R) 2x Strategy Fund, a managed leveraged & inverse mutual fund from Guggenheim.
Its expense ratio is 2.09% — about $209 a year on every $10,000 invested, more expensive than 94% of leveraged & inverse funds we track.
It returned −38.4% over one year, −31.0% a year over five years, −37.2% a year over ten (as of Dec 31, 2025, per its prospectus).
With $9.1 million in net assets and 8 holdings, its largest position is J.p. Morgan Securities Llc (36.6%) and the top 10 make up 84.7% of the portfolio.
This share class carries a front-end sales charge of up to 4.75%; a no-load class or ETF alternative can avoid it.
What to watch
- Expensive for its category (2.09%)
- 5-year return in the bottom quarter of its category
- Concentrated: top 10 holdings are 84.7% of assets
- Front-end sales load up to 4.75%
- 12b-1 marketing fee of 0.25% a year
Updated Nov 19, 2026
What RYVTX invests in
The Fund seeks to provide investment results that match, before fees and expenses, the performance of a specific benchmark on a daily basis. The Funds current benchmark is 200% of the inverse (opposite) of the performance of the NASDAQ-100 Index (the underlying index). The Fund does not seek to achieve its investment objective over a period of time greater than one day.
The Fund employs as its investment strategy a program of engaging in short sales of securities generally included in the underlying index and investing in derivative instruments, which primarily consist of equity index swaps and swaps on exchange-traded funds, futures contracts, and options on securities, securities indices, and futures contracts. While the Fund may write (sell) and purchase swaps, it expects primarily to write swaps. The Advisor attempts to consistently apply leverage to increase the Funds exposure to -200% of the underlying index and expects to rebalance the Funds holdings daily to maintain such exposure. The Funds investment in derivatives referencing (i) the underlying index, or (ii) securities included in the underlying index, serves as a substitute for directly selling short each of the securities included in the underlying index and produces inverse exposure to…
From the fund's prospectus (filed Jul 29, 2026).
RYVTX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| RYVTX | −38.4% | −31.0% | −37.2% |
| Leveraged & Inverse median | −7.7% | −11.8% | −13.5% |
Source: Fund prospectus, as of Dec 31, 2025
What RYVTX costs
On a $10,000 investment, RYVTX's 2.09% expense ratio costs about $209 a year. The prospectus estimates $2,871 in total costs over 10 years (assuming 5% annual returns). The median leveraged & inverse fund charges 1.31%.
RYVTX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | J.p. Morgan Securities Llc | 36.55% |
| 2 | Merrill Lynch, Pierce, Fenner & Smith Incorporated | 36.55% |
| 3 | United States Of America - Bureau Of The Public Debt | 10.98% |
| 4 | Dreyfus Treasury Obligations Cash Management | 6.86% |
| 5 | Goldman Sachs International | 0.13% |
| 6 | Chicago Mercantile Exchange | -0.07% |
| 7 | Barclays Capital Inc. | -0.73% |
| 8 | Bnp Paribas Securities Corp. | -5.61% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 84.7% of the fund. See all top 25 holdings and asset mix →